PT  - JOURNAL ARTICLE
AU  - Carneiro, Beatriz A.
AU  - Guerreiro-Costa, Lívia N. F.
AU  - Lins-Silva, Daniel H.
AU  - Faria-Guimarães, Daniela
AU  - Souza, Lucca S.
AU  - Leal, Gustavo C.
AU  - Fontes, Ana Teresa C.
AU  - Beanes, Graziele
AU  - Costa, Ryan S.
AU  - Quarantini, Lucas C.
TI  - MicroRNAs as diagnostic biomarkers and predictors of antidepressant response in major depressive disorder: a systematic review
AID  - 10.1101/2024.02.17.24302977
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.02.17.24302977
4099  - http://medrxiv.org/content/early/2024/02/18/2024.02.17.24302977.short
4100  - http://medrxiv.org/content/early/2024/02/18/2024.02.17.24302977.full
AB  - Despite the hardships of major depressive disorder (MDD), biomarkers for the diagnosis and pharmacological management of this condition are lacking. MicroRNAs are epigenetic mechanisms that could provide promising MDD biomarkers. Our aim was to summarize the findings and provide validation for the selection and use of specific microRNAs as biomarkers in the diagnosis and treatment of MDD. A systematic review was conducted using the PubMed/MEDLINE, Cochrane, PsycINFO, Embase, and LILACS databases from March to May 2022, with clusters of terms based on “microRNA” and “antidepressant”. Studies involving human subjects, animal models, and cell cultures were included, whereas those that evaluated herbal medicines, non-pharmacological therapies, or epigenetic mechanisms other than miRNA were excluded. The review revealed differences in the expression of various microRNAs when considering the time of assessment (before or after antidepressant treatment) and the population studied. However, due to the heterogeneity of the microRNAs investigated, the limited size of the samples, and the wide variety of antidepressants used, few conclusions could be made. Despite the observed heterogeneity, the following microRNAs were determined to be important factors in MDD and the antidepressant response: mir-1202, mir-135, mir-124, and mir-16. The findings indicate the potential for the use of microRNAs as biomarkers for the diagnosis and treatment of MDD; however, more homogeneous studies are needed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research received backing from the Programa de Pesquisa para o SUS (PPSUS/BA) under grant number 003/2017, a publicly-funded research initiative. Additionally, it was partially funded through Coordena&ccedil&atildeo de Aperfei&ccediloamento de Pessoal de N&iacutevel Superior Brasil (CAPES) Finance Code 001.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript